Researchers say GLP-1 drugs are still rarely given to young children, but the number of kids getting them is climbing fast.
Recap by typeshit. Full story at News4JAX.
Pratt, a psychology professor who studies the circuits behind food motivation, walks through what neuroscience shows about these drugs.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
Kaydo calls retatrutide the most exciting obesity drug in the pipeline and explains its triple action on GLP-1, GIP and glucagon receptors before adding caveats.
On Longevity.Technology's podcast, the two contrast well-studied GLP-1 drugs with thinly tested compounds and discuss gray-market risks and testing.
Loading…